These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1601998)

  • 1. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.
    Zenobi PD; Graf S; Ursprung H; Froesch ER
    J Clin Invest; 1992 Jun; 89(6):1908-13. PubMed ID: 1601998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
    Morrow LA; O'Brien MB; Moller DE; Flier JS; Moses AC
    J Clin Endocrinol Metab; 1994 Jul; 79(1):205-10. PubMed ID: 8027228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.
    Kerr D; Tamborlane WV; Rife F; Sherwin RS
    J Clin Invest; 1993 Jan; 91(1):141-7. PubMed ID: 8423214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.
    Katz LE; Ferry RJ; Stanley CA; Collett-Solberg PF; Baker L; Cohen P
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3117-24. PubMed ID: 10487673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs.
    Douglas RG; Gluckman PD; Ball K; Breier B; Shaw JH
    J Clin Invest; 1991 Aug; 88(2):614-22. PubMed ID: 1864971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
    Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
    J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.
    Hartman ML; Clayton PE; Johnson ML; Celniker A; Perlman AJ; Alberti KG; Thorner MO
    J Clin Invest; 1993 Jun; 91(6):2453-62. PubMed ID: 8514857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.
    Schalch DS; Turman NJ; Marcsisin VS; Heffernan M; Guler HP
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1563-8. PubMed ID: 8263142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans.
    Rennert NJ; Caprio S; Sherwin RS
    J Clin Endocrinol Metab; 1993 Mar; 76(3):804-6. PubMed ID: 8445040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans.
    Mauras N; Horber FF; Haymond MW
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1192-7. PubMed ID: 1430078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM; Hartman ML; Pezzoli SS; Harrell FE; Hintz RL; Alberti KG; Thorner MO
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
    Cusi K; DeFronzo R
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) on glucose and insulin levels in healthy males.
    Morgan JM; Piraino AJ; Saris SD; Capuzzi DM
    Int J Clin Pharmacol Ther; 1994 May; 32(5):235-9. PubMed ID: 7921517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery.
    Mauras N; Martha PM; Quarmby V; Haymond MW
    Am J Physiol; 1997 Apr; 272(4 Pt 1):E628-33. PubMed ID: 9142884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.
    Vestergaard H; Rossen M; Urhammer SA; Müller J; Pedersen O
    Eur J Endocrinol; 1997 May; 136(5):475-82. PubMed ID: 9186267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance.
    Schoenle EJ; Zenobi PD; Torresani T; Werder EA; Zachmann M; Froesch ER
    Diabetologia; 1991 Sep; 34(9):675-9. PubMed ID: 1955101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemic and insulin response to a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) in healthy males.
    Morgan JM; Saris SD; Capuzzi DM; Good WR; John VA; Guler HP; Seaman J; Piraino AJ
    J Clin Pharmacol; 1993 Apr; 33(4):366-72. PubMed ID: 8473552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.